CG Oncology (CGON) Non-Current Assets (2023 - 2026)
CG Oncology posted quarterly Non-Current Assets of $33.1 million for Q1 2026, up 22.71% year-on-year from $27.0 million in Q1 2025, and up 3.12% on a QoQ basis from $32.1 million in Q4 2025.
CG Oncology (CGON) has 4 years of Non-Current Assets data on file, last reported at $33.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 22.71% year-over-year to $33.1 million; the trailing twelve-month figure through Mar 2026 stood at $127.8 million (up 349.39% YoY), and the FY2025 full-year result was $32.1 million, up 5371.38% from the prior year.
- Non-Current Assets for Q1 2026 stood at $33.1 million, up from $32.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $34.1 million in Q3 2025 and bottomed at $391000.0 in Q3 2024.
- The 4-year median for Non-Current Assets is $16.1 million (2023), against an average of $16.2 million.
- The widest annual swing landed in 2024, when Non-Current Assets slumped 88.66%; it then jumped 8627.11% in 2025.
- A 4-year view of Non-Current Assets shows it stood at $5.2 million in 2023, then plunged by 88.66% to $587000.0 in 2024, then jumped by 5371.38% to $32.1 million in 2025, then grew by 3.12% to $33.1 million in 2026.
- The last three Non-Current Assets figures came in at $33.1 million (Q1 2026), $32.1 million (Q4 2025), and $34.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | CG Oncology | 5.01 Bn | 5.01 Bn | -1.88 Mn | 33.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.12 Mn |
| Dec 31, 2025 | 32.12 Mn |
| Sep 30, 2025 | 34.12 Mn |
| Jun 30, 2025 | 28.42 Mn |
| Mar 31, 2025 | 26.99 Mn |
| Dec 31, 2024 | 587,000.00 |
| Sep 30, 2024 | 391,000.00 |
| Jun 30, 2024 | 466,000.00 |
| Mar 31, 2024 | 498,000.00 |
| Dec 31, 2023 | 5.18 Mn |